These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 31434080)

  • 1. Glomerular Hyperfiltration or Microalbuminuria as an Early Marker of Fabry Nephropathy.
    Moiseev S; Karovaikina E; Bulanov N; Moiseev A; Zykova A; Bobkova I
    Nephron; 2019; 143(2):133-134. PubMed ID: 31434080
    [No Abstract]   [Full Text] [Related]  

  • 2. Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease.
    Riccio E; Sabbatini M; Bruzzese D; Annicchiarico Petruzzelli L; Pellegrino A; Spinelli L; Esposito R; Imbriaco M; Feriozzi S; Pisani A;
    Nephron; 2019; 141(1):10-17. PubMed ID: 30466100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Biomarkers of Fabry Nephropathy: A Review of the Literature.
    Riccio E; Sabbatini M; Capuano I; Pisani A
    Nephron; 2019; 143(4):274-281. PubMed ID: 31614349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New biomarkers defining a novel early stage of Fabry nephropathy: A diagnostic test study.
    Aguiar P; Azevedo O; Pinto R; Marino J; Baker R; Cardoso C; Ducla Soares JL; Hughes D
    Mol Genet Metab; 2017 Jun; 121(2):162-169. PubMed ID: 28526293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease.
    Moura AP; Hammerschmidt T; Deon M; Giugliani R; Vargas CR
    Clin Chim Acta; 2018 Mar; 478():62-67. PubMed ID: 29274327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of renal pathology and dysfunction in children with Fabry disease.
    Ramaswami U; Najafian B; Schieppati A; Mauer M; Bichet DG
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):365-70. PubMed ID: 20056758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy and Fabry nephropathy.
    Warnock DG; Daina E; Remuzzi G; West M
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathogenicity of glomerular hyperfiltration, a question of glomerular tolerance?].
    Wüstenberg PW; Dabels J
    Z Gesamte Inn Med; 1990 Apr; 45(8):210-4. PubMed ID: 2198716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microalbuminuria and hyperfiltration in subjects with nephro-urological disorders.
    Cachat F; Combescure C; Chehade H; Zeier G; Mosig D; Meyrat B; Frey P; Girardin E
    Nephrol Dial Transplant; 2013 Feb; 28(2):386-91. PubMed ID: 23223226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal disease in adult Nigerians with sickle cell anemia: a report of prevalence, clinical features and risk factors.
    Bolarinwa RA; Akinlade KS; Kuti MA; Olawale OO; Akinola NO
    Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):171-5. PubMed ID: 22237246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystatin C as a marker of early changes of renal function in Fabry nephropathy.
    Feriozzi S; Germain DP; Di Vito R; Legrand A; Ricci R; Barbey F
    J Nephrol; 2007; 20(4):437-43. PubMed ID: 17879210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nephropathy in Fabry disease: possibilities for the radical improvement of prognosis for orphan diseases].
    Fomin VV; Pulin AA; Mukhin NA
    Ter Arkh; 2013; 85(6):4-9. PubMed ID: 23866592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabry Nephropathy: An Evidence-Based Narrative Review.
    Del Pino M; Andrés A; Bernabéu AÁ; de Juan-Rivera J; Fernández E; de Dios García Díaz J; Hernández D; Luño J; Fernández IM; Paniagua J; Posada de la Paz M; Rodríguez-Pérez JC; Santamaría R; Torra R; Ambros JT; Vidau P; Torregrosa JV
    Kidney Blood Press Res; 2018; 43(2):406-421. PubMed ID: 29558749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent developments in genetic kidney diseases].
    Liebau MC; Benzing T
    Dtsch Med Wochenschr; 2011 May; 136(19):1014-20. PubMed ID: 21544793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glomerular hyperfiltration and albuminuria in critically ill patients.
    Fuster-Lluch O; Gerónimo-Pardo M; Peyró-García R; Lizán-García M
    Anaesth Intensive Care; 2008 Sep; 36(5):674-80. PubMed ID: 18853585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glomerular hyperfiltration in microalbuminuric NIDDM patients.
    Vedel P; Obel J; Nielsen FS; Bang LE; Svendsen TL; Pedersen OB; Parving HH
    Diabetologia; 1996 Dec; 39(12):1584-9. PubMed ID: 8960846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function.
    Aakre KM; Tøndel C; Brun A; Svarstad E
    Clin Nephrol; 2009 Feb; 71(2):118-24. PubMed ID: 19203503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperfiltration as a factor in the progression of chronic kidney diseases].
    Kutyrina IM; Rogov VA; Shestakova MV; Zverev KV
    Ter Arkh; 1992; 64(6):10-5. PubMed ID: 1440323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperfiltration in normoalbuminuric type 1 diabetic patients: relationship with urinary albumin excretion rate.
    Bulum T; Kolarić B; Prkacin I; Duvnjak L
    Coll Antropol; 2013 Jun; 37(2):471-6. PubMed ID: 23940992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.